P0394EFFICACY AND SAFETY OF A CHINESE PATENT MEDICINE-SHENYANKANGFU TABLETS FOR PRIMARY GLOMERULONEPHRITIS:A RANDOMISED CONTROLLED TRIAL
Jie Wu(First Affiliated Hospital of Jinan University), Xusheng Liu(Guangdong Provincial Hospital of Traditional Chinese Medicine), Jingai Fang(Shanxi Medical University), Guangyan Cai(Chinese PLA General Hospital), Hongtao Yang(First Teaching Hospital of Tianjin University of Traditional Chinese Medicine), Yueyi Deng(Shanghai University of Traditional Chinese Medicine), Xiangmei Chen(State Administration of Traditional Chinese Medicine of the People's Republic of China), Yani He(PLA Army Engineering University), Yongli Zhan(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Li(University of California, Irvine), Shuwei Duan(People's Liberation Army No. 150 Hospital), Zhaohui Ni(Shanghai Jiao Tong University)
Cited by 0
Related Papers
Exosomal miR-21 from tubular cells contributes to renal fibrosis by activating fibroblasts via targeting PTEN in obstructed kidneys
|Theranostics|2021|174
A Multicenter Application and Evaluation of the Oxford Classification of IgA Nephropathy in Adult Chinese Patients
|American Journal of Kidney Diseases|2012|157
LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-β–Induced Angiogenesis
|Journal of the American Society of Nephrology|2019|149
<scp>H</scp>ermansky–<scp>P</scp>udlak syndrome: pigmentary and non‐pigmentary defects and their pathogenesis
|Pigment Cell & Melanoma Research|2012|134